|
|
Blood, 1 March 2008, Vol. 111, No. 5, pp. 2548-2555.
Prepublished online as a Blood First Edition Paper on November 26, 2007; DOI 10.1182/blood-2007-02-070342.
Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group
Nita L. Seibel1,
Peter G. Steinherz2,
Harland N. Sather3,
James B. Nachman4,
Cynthia DeLaat5,
Lawrence J. Ettinger6,
David R. Freyer7,
Leonard A. Mattano, Jr8,
Caroline A. Hastings9,
Charles M. Rubin4,
Kathy Bertolone10,
Janet L. Franklin11,
Nyla A. Heerema12,
Torrey L. Mitchell13,
Allan F. Pyesmany14,
Mei K. La3,
Cheryl Edens15, and
Paul S. Gaynon11
1 Hematology/Oncology, Children's National Medical Center and George Washington University School of Medicine and Public Health, Washington, DC;
2 Memorial Sloan Kettering Cancer Center, New York, NY;
3 Group Operations Center, Children's Oncology Group, Arcadia, CA;
4 University of Chicago Comer Children's Hospital, IL;
5 Cincinnati Children's Hospital Medical Center, OH;
6 St Peter's University Hospital, New Brunswick, NJ;
7 DeVos Children's Hospital, Grand Rapids, MI;
8 Kalamazoo Center for Medical Studies, MI;
9 Children's Hospital and Research Center Oakland, CA;
10 Kosair Children's Hospital, Louisville, KY;
11 Children's Hospital of Los Angeles, CA;
12 Ohio State University College of Medicine, Columbus;
13 Raymond Blank Children's Hospital, Des Moines, IA;
14 Izaak Walton Killam (IWK) Health Center, Halifax, NS; and
15 Department of Hematology/Oncology, Vanderbilt University, Nashville, TN
Longer and more intensive postinduction intensification (PII) improved the outcome of children and adolescents with "higher risk" acute lymphoblastic leukemia (ALL) and a slow marrow response to induction therapy. In the Children's Cancer Group study (CCG-1961), we tested longer versus more intensive PII, using a 2 x 2 factorial design for children with higher risk ALL and a rapid marrow response to induction therapy. Between November 1996 and May 2002, 2078 children and adolescents with newly diagnosed ALL (1 to 9 years old with white blood count 50 000/ or more, or 10 years of age or older with any white blood count) were enrolled. After induction, 1299 patients with marrow blasts less than or equal to 25% on day 7 of induction (rapid early responders) were randomized to standard or longer duration (n = 651 + 648) and standard or increased intensity (n = 649 + 650) PII. Stronger intensity PII improved event-free survival (81% vs 72%, P < .001) and survival (89% vs 83%, P = .003) at 5 years. Differences were most apparent after 2 years from diagnosis. Longer duration PII provided no benefit. Stronger intensity but not prolonged duration PII improved outcome for patients with higher-risk ALL. This study is registered at http://clinicaltrials.gov as NCT00002812
[ClinicalTrials.gov]
.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. B. Nachman, M. K. La, S. P. Hunger, N. A. Heerema, P. S. Gaynon, C. Hastings, L. A. Mattano Jr, H. Sather, M. Devidas, D. R. Freyer, et al.
Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group
J. Clin. Oncol.,
November 1, 2009;
27(31):
5189 - 5194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-H. Pui
Toward a Total Cure for Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
November 1, 2009;
27(31):
5121 - 5123.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Korn, B. Freidlin, and M. Mooney
Stopping or Reporting Early for Positive Results in Randomized Clinical Trials: The National Cancer Institute Cooperative Group Experience From 1990 to 2005
J. Clin. Oncol.,
April 1, 2009;
27(10):
1712 - 1721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. R. Freyer, N. L. Seibel, M. K La, M. Devidas, W. L. Carroll, S. P. Hunger, and P. S. Gaynon
Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children's Oncology Group (COG).
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
917 - 917.
[Abstract]
|
 |
|

|
 |

|
 |
 
D. Bhojwani, H. Kang, R. X. Menezes, W. Yang, H. Sather, N. P. Moskowitz, D.-J. Min, J. W. Potter, R. Harvey, S. P. Hunger, et al.
Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
J. Clin. Oncol.,
September 20, 2008;
26(27):
4376 - 4384.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Pulte, A. Gondos, and H. Brenner
Trends in 5- and 10-year Survival After Diagnosis with Childhood Hematologic Malignancies in the United States, 1990-2004
J Natl Cancer Inst,
September 17, 2008;
100(18):
1301 - 1309.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. L. Seibel
Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls
Hematology,
January 1, 2008;
2008(1):
374 - 380.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|